

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mel H. Epstein, Kjesten A. Wiig, and Jeroen Verheijen  
Application No.: 10/791,223 Group: 1614  
Filed: March 2, 2004 Examiner: Brian S. Kwon  
Confirmation No.: 3953  
For: METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT  
AND ALZHEIMER'S DISEASE



CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
3/5/07	Angelina Bellanton
Date	Signature
Angelina Bellanton	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:  
☐ a Statement under 37 CFR 1.97(e), as checked below, or  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:  
☐ a Statement under 37 CFR 1.97(e), as checked below, and  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application file.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

## Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

*Applies to original applications (other than design) filed on or after May 29, 2000*

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
  - ☒ Copies of the cited references, C269-C284, are enclosed.
    - ☐ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.
  - ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
  - ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
    - ☐ the explanation provided on the attached sheet.
    - ☐ the explanation provided in the Specification.
    - ☐ submission of the enclosed International Search Report.
    - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
    - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:  
*(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)*

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
 Examiner

\_\_\_\_\_  
 Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Mary K. Murray


Registration No. 47,813

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: March 5, 2007

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>   March 5, 2007 (Use separate sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein	FILING DATE March 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C269	Chertkow, H., "Mild Cognitive Impairment," <i>Curr. Opin. in Neurol.</i> 15:401-407 (2002).
C270	Clarke, A., "A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition," <i>J. Neural. Transm.</i> 110:1241-1255 (2003).
C271	Gauthier, S., <i>et al.</i> , "Mild Cognitive Impairment," <i>The Lancet</i> 367:1262-1270 (2006).
C272	Grundman, M., <i>et al.</i> , "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," <i>Arch. Neurol.</i> 61:59-66 (2004).
C273	Halgren, E., <i>et al.</i> , "Human Hippocampal Formation EEG Desynchronizes During Attentiveness and Movement," <i>Electroencephalography and Clinical Neurophysiology</i> 44:778-781 (1978).
C274	Lynch, G., <i>et al.</i> , "The Nature and Causes of Hippocampal Long-term Potentiation," <i>Progress in Brain Research</i> 83:233-250 (1990).
C275	Mild Cognitive Impairment. Alzheimer's Society Information Sheet [online], March 2005. Retrieved from the Internet <URL: <a href="http://www.alzheimers.org.uk">http://www.alzheimers.org.uk</a> >.
C276	Mild Cognitive Impairment-Alzheimer's Disease Part XVI [online], November 2006 [retrieved on 2007-01-24]. Retrieved from the Internet <URL: <a href="http://www.therubins.com">http://www.therubins.com</a> >.
C277	Meeker, J.S. and Reynolds, P.C., "Postmortem Tissue Methamphetamine Concentrations Following Selegiline Administration," <i>J. of Analytical Toxicology</i> 14:330-331 (1990).
C278	Nickel, B., <i>et al.</i> , "Evaluation of Physical Dependence Liability of <i>l</i> -deprenyl (Selegiline) in Animals," <i>Clinical Pharmacology &amp; Therapeutics</i> , 56(6):757-767 (1994).
C279	Petersen, R.C., <i>et al.</i> , "Current Concepts in Mild Cognitive Impairment," <i>Arch Neurol.</i> 58:1985-1992 (2001).
C280	Uchida, S., <i>et al.</i> , "Cortical Oscillations in Human Medial Temporal Lobe During Wakefulness and All-night Sleep," <i>Brain Research</i> 891:7-19 (2001).
C281	Yasar, S., <i>et al.</i> , "Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(-)-Deprenyl]," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 317(1):387-394 (2006).
C282	Kwon, Y. S., <i>et al.</i> , "Selegiline Potentiates the Effects of Egb 761 in Response to Ischemic Brain Injury," <i>Neurochemistry International</i> 45:157-170 (2004).

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>PTO-1449 REPRODUCED</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  March 5, 2007  (Use several sheets if necessary)	<b>ATTORNEY DOCKET NO.</b> 3474.1001-011		<b>APPLICATION NO.</b> 10/791,223
	<b>FIRST NAMED INVENTOR</b> Mel H. Epstein		<b>FILING DATE</b> March 2, 2004
	<b>EXAMINER</b> Unknown	<b>CONFIRMATION NO.</b> 3953	<b>GROUP</b> 1614

C283	Semkova, I., <i>et al.</i> , "Selegiline Enhances NGF Synbthesis and Protects Central Nervous System Neurons from Excitotoxic and Ischemic Damage," <i>European Journal of Pharmacology</i> 315:19-30 (1996).
C284	Sivenius, J., <i>et al.</i> , "Selegiline Treatment Facilitates Recovery After Stroke," <i>Neurorehabilitation and Neural Repair</i> 15:183-190 (2001).

697835\_1.DOC

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------